Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration

BACKGROUND: Epidermal growth factor receptor (EGFR) in trans-C797S alteration has been considered as one of the mechanisms, which leads to the resistance to third-generation tyrosine kinase inhibitors (TKI). Several reports have suggested that combination therapy with first- and third-generation TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianxin, Wang, Junhui, Wu, Xilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358086/
https://www.ncbi.nlm.nih.gov/pubmed/32753903
http://dx.doi.org/10.2147/OTT.S262594
_version_ 1783558786376531968
author Chen, Jianxin
Wang, Junhui
Wu, Xilin
author_facet Chen, Jianxin
Wang, Junhui
Wu, Xilin
author_sort Chen, Jianxin
collection PubMed
description BACKGROUND: Epidermal growth factor receptor (EGFR) in trans-C797S alteration has been considered as one of the mechanisms, which leads to the resistance to third-generation tyrosine kinase inhibitors (TKI). Several reports have suggested that combination therapy with first- and third-generation TKIs might be effective for acquired trans-C797S alteration. CASE PRESENTATION: Herein, we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S mutations with co-occurring CTNNB1 alteration showing a negative response to combination therapy with first- and third-generation TKIs. CONCLUSION: Our report highlights the importance of deploying more informed molecular diagnosis and real-time monitoring strategies to detect co-alterations that drive disease progression and drug resistance, in order to find more effective treatment.
format Online
Article
Text
id pubmed-7358086
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73580862020-08-03 Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration Chen, Jianxin Wang, Junhui Wu, Xilin Onco Targets Ther Case Report BACKGROUND: Epidermal growth factor receptor (EGFR) in trans-C797S alteration has been considered as one of the mechanisms, which leads to the resistance to third-generation tyrosine kinase inhibitors (TKI). Several reports have suggested that combination therapy with first- and third-generation TKIs might be effective for acquired trans-C797S alteration. CASE PRESENTATION: Herein, we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S mutations with co-occurring CTNNB1 alteration showing a negative response to combination therapy with first- and third-generation TKIs. CONCLUSION: Our report highlights the importance of deploying more informed molecular diagnosis and real-time monitoring strategies to detect co-alterations that drive disease progression and drug resistance, in order to find more effective treatment. Dove 2020-07-09 /pmc/articles/PMC7358086/ /pubmed/32753903 http://dx.doi.org/10.2147/OTT.S262594 Text en © 2020 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Chen, Jianxin
Wang, Junhui
Wu, Xilin
Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title_full Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title_fullStr Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title_full_unstemmed Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title_short Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
title_sort primary resistance to combination therapy with first- and third-generation egfr tyrosine kinase inhibitors of lung adenocarcinoma harboring egfr 19del/t790m/in trans-c797s mutations with co-occurring ctnnb1 alteration
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358086/
https://www.ncbi.nlm.nih.gov/pubmed/32753903
http://dx.doi.org/10.2147/OTT.S262594
work_keys_str_mv AT chenjianxin primaryresistancetocombinationtherapywithfirstandthirdgenerationegfrtyrosinekinaseinhibitorsoflungadenocarcinomaharboringegfr19delt790mintransc797smutationswithcooccurringctnnb1alteration
AT wangjunhui primaryresistancetocombinationtherapywithfirstandthirdgenerationegfrtyrosinekinaseinhibitorsoflungadenocarcinomaharboringegfr19delt790mintransc797smutationswithcooccurringctnnb1alteration
AT wuxilin primaryresistancetocombinationtherapywithfirstandthirdgenerationegfrtyrosinekinaseinhibitorsoflungadenocarcinomaharboringegfr19delt790mintransc797smutationswithcooccurringctnnb1alteration

Ejemplares similares